Drug Profile
Levofloxacin ophthalmic - Daiichi Sankyo
Alternative Names: Cravit Ophthalmic; DE-108; Iquix 1.5%; Oftaquix; QuixinLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Developer Daiichi Sankyo Company; Santen Pharmaceutical
- Class Anti-infectives; Antibacterials; Fluoroquinolones; Small molecules
- Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Corneal ulcer; Infectious conjunctivitis; Ophthalmic infections
Most Recent Events
- 01 Sep 2015 Santen Pharmaceutical initiates enrolment in a phase III trial for Ophthalmic infections in South Korea (NCT02573610)
- 01 Nov 2012 South Korean Food and Drug Administration declines to approve 1.5% ophthalmic solution of levofloxacin for treatment of Conjunctivitis and other Ophthalmic infections
- 07 Feb 2012 Preregistration for Conjunctivitis in South Korea (Ophthalmic, 1.5%)